Rectal cancer is a common disease of elderly people. However, patients over 70 years of age are often not included in clinical trials. There is a lack of data concerning the use of radiochemotherapy with capecitabine in elderly patients. The aim of this study was to retrospectively evaluate the impact of preoperative radiochemotherapy with capecitabine on downstaging and sphincter preservation and to assess treatment compliance and toxicity in elderly patients.
Methods
Twenty-six patients with resectable locally advanced rectal cancer (stage II-III/TNM) aged >70 years received preoperative radiotherapy and concurrent oral capecitabine 825 mg/m2 twice daily during the whole period of radiotherapy. Two patients who refused surgery after chemoradiation therapy were excluded from the analysis.
Results
Eighty-one percent of patients underwent anterior resection and 18.1% underwent abdominoperineal resection. Overall tumor downstaging, considering both T and N categories, was observed in 18/24 patients (75%). Treatment compliance was good and toxicity rates were similar to those of younger people.
Conclusions
Age is not a contraindication to any therapy and elderly patients who can tolerate radiochemotherapy should be treated like younger patients. Preoperative radiochemotherapy with capecitabine for patients aged >70 years has a good impact on tumor downstaging, increases the feasibility of sphincter-preserving surgery, and is also safe and well tolerated.
ParkinM.D., WhelanS.L., FerlayJ., TeppoL., ThomasD.B.: Cancer incidence in five continents, vol VIII. IARC Scientific Publications, 155, IARC, Lyon, 2002.
2.
WobbesT.: Carcinoma of the colon and rectum in geriatric patients.Age Ageing, 14: 321–326, 1985.
3.
TrimbleE.L., CarterC.L., CainD., FreidlinB., UngerleiderR.S., FriedmanM.A.: Representation of older patients in cancer treatment trials.Cancer, 74: 2208–2014, 1994.
BrodyJ.A., SchneiderE.L.: Diseases and disorders of ageing: an hypothesis.J Chron Dis, 39: 871–876, 1986.
6.
De MarcoM.F., Janssen-HeijnenM.L.G., van der HeijdenL.H., CoeberghJ.W.: Comorbidity and colorectal cancer according to subsite and stage: a population-based study.Eur J Cancer, 36: 95–99, 2000.
7.
LemmensVEPP, Janssen-HeijnenM.L.G., VerheijC.D., HoutermanS., Repelaer van DrielO.J., CoeberghJ.W.: Comorbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer.Br J Surg, 92: 615–623, 2005.
8.
AbirF., AlvaS., LongoW.E.: The management of rectal cancer in the elderly.Surg Oncol, 13: 223–234, 2004.
9.
Swedish Rectal Cancer Trial:Improved survival with preoperative radiotherapy in resectable rectal cancer.N Engl J Med, 336: 980–987, 1997.
10.
SauerR., BeckerH., HohenbergerW., RödelC., WittekindC., FietkauR., MartusP., TschmelitschJ., HagerE., HessC.F., KarstensJ.H., LierschT., SchmidbergerH., RaabR.; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer.N Engl J Med, 351: 1731–1740, 2004.
11.
Colorectal Cancer Collaborative Group:Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomized trials.Lancet, 358: 1291–1304, 2001.
12.
KapiteijnE., MarijnenC.A., NagtegaalI.D., PutterH., SteupW.H., WiggersT., RuttenH.J., PahlmanL., GlimeliusB., van KriekenJ.H., LeerJ.W., van de VeldeC.J.; Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.N Engl J Med, 345: 638–646, 2001.
13.
CammaC., GiuntaM., FioricaF., PagliaroL., CraxìA., CottoneM.: Preoperative radiotherapy for resectable rectal cancer: a meta-analysis.JAMA, 284: 1008–1015, 2000.
14.
KimJ., KimJ., JangJ.: The treatment results of preoperative concurrent chemoradiation in locally advanced rectal cancer.J Korean Cancer Assoc, 32: 933–942, 2000.
15.
JanjanN.A., KhooV.S., AbbruzzeseJ., PazdurR., DubrowR., ClearyK.R., AllenP.K., LynchP.M., GloberG., WolffR., RichT.A., SkibberJ.: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The MD Anderson Cancer Center experience.Int J Radiat Oncol Biol Phys, 44: 1027–1038, 1999.
16.
RuttenH., den DulkM., LemmensV., NieuwenhuijzenG., KrijnenP., Jansen-LandheerM., van de Poll FranseL., CoeberghJ.W., MartijnH., MarijnenC., van de VeldeC.: Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery.Eur J Cancer, 43: 2295–2300, 2007.
17.
Gastrointestinal Tumor Study Group GITSG:Radiation therapy and fluorouracil with and without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum.J Clin Oncol, 10: 549–557, 1992.
18.
O'ConnellM.J., MartensonJ.A., WieandH.S., KrookJ.E., MacdonaldJ.S., HallerD.G., MayerR.J., GundersonL.L., RichT.A.: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery.N Engl J Med, 331: 502–507, 1994.
19.
SmalleyR.S., BenedettiJ.K., WilliamsonS.K., RobertsonJ.M., EstesN.C., MaherT., FisherB., RichT.A., MartensonJ.A., KuglerJ.W., BensonAB3rd, HallerD.G., MayerR.J., AtkinsJ.N., CrippsC., PedersenJ., PerimanP.O., TanakaM.S.Jr., LeichmanC.G., MacdonaldJ.S.: Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.J Clin Oncol, 24: 3542–3547, 2006.
20.
SargentD., GoldbergR., JacobsonS.D., MacdonaldJ.S., LabiancaR., HallerD.G., ShepherdL.E., SeitzJ.F., FranciniG.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.N Engl J Med, 345: 1091–1097, 2001.
21.
PopescuR.A., NormanA., RossP.J., ParikhB., CunninghamD.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.J Clin Oncol, 17: 2412–2418, 1999.
22.
DesaiS.P., El-RayesB.F., Ben-JosefE., GreensonJ.K., KnolJ.A., HuangE.H., GriffithK.A., PhilipP.A., McGinnC.J., ZalupskiM.M.: A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.Am J Clin Oncol, 30: 340–345, 2007.
23.
SchullerJ., CassidyJ., DumontE., RoosB., DurstonS., BankenL., UtohM., MoriK., WeidekammE., ReignerB.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.Cancer Chemother Pharmacol, 45: 291–297, 2000.
24.
JudsonI.R., BealeP.J., TrigoJ.M., AherneW., CromptonT., JonesD., BushE., ReignerB.: A human capecitabine excretion balance and pharmacokinetic study after administration of a single dose of 14C-labelled drug.Invest New Drugs, 17: 49–56, 1999.
25.
KimD.Y., JungK.H., KimT.H., KimD.W., ChangH.J., JeongJ.Y., KimY.H., SonS.H., YunT., HongC.W., SohnD.K., LimS.B., ChoiH.S., JeongS.Y., ParkJ.G.: Comparison of 5-fluoruracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.Int J Radiat Oncol Biol Phys, 67: 378–384, 2007.
26.
TwelvesC., BoyerM., FindlayM., CassidyJ., WeitzelC., BarkerC., OsterwalderB., JamiesonC., HiekeK.; Xeloda Colorectal Cancer Study Group: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.Eur J Cancer, 37: 597–604, 2001.
27.
HoffP.M., AnsariR., BatistG., CoxJ., KochaW., KupermincM., MarounJ., WaldeD., WeaverC., HarrisonE., BurgerH.U., OsterwalderB., WongA.O., WongR.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.J Clin Oncol, 19: 2282–2292, 2001.
28.
ScheithauerW., McKendrickJ., BegbieS., BornerM., BurnsW.I., BurrisH.A., CassidyJ., JodrellD., KoralewskiP., LevineE.L., MarschnerN., MarounJ., Garcia-AlfonsoP., TujakowskiJ., Van HazelG., WongA., ZaluskiJ., TwelvesC; X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.Ann Oncol, 14: 1735–1743, 2003.
29.
CassidyJ., TwelvesC., Van CutsemE., HoffP., BajettaE., BoyerM., BugatR., BurgerU., GarinA., GraevenU., McKendricJ., MarounJ., MarshallJ., OsterwalderB., Pérez-MangaG., RossoR., RougierP., SchilskyR.L.; Capecitabine Colorectal Cancer Study Group: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.Ann Oncol, 13: 566–575, 2002.
30.
American Joint Committee on Cancer:Colon and rectum. In: AJCC Cancer Staging Manual, 6th ed, pp 113–124, Springer, New York, 2002.
31.
ConwellY., ForbesN., CoxC., CaineE.: Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale.J Am Geriatr Soc, 41: 38–41, 1993.
32.
International Commission on Radiation Units and Measurements:Prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). ICRU Report 62, ICRU, Bethesda, MD, 1999.
33.
CapirciC., PolicoC., MandolitiG.: Dislocation of small bowel volume within box pelvic treatment fields, using new “up down table” device.Int J Radiat Oncol Biol Phys, 51: 465–473, 2001.
34.
MandardA.M., DalibardF., MandardJ.C., MarnayJ., Henry-AmarM., PetiotJ.F., RousselA., JacobJ.H., SegolP., SamamaG., OlivierJ.M., BonvalotS., GignouxM.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma.Cancer, 73: 2680–2686, 1994.
35.
GlimeliusB., HolmT., BlomqvistL.: Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer-a systematic overview.Rev Recent Clin Trials, 3: 204–211, 2008.
FietkauR., RodelC., HohenbergerW., RaabR., HessC., LierschT., BeckerH., WittekindC., HutterM., HagerE., KarstensJ., EwaldH., ChristenN., JagoditschM., MartusP., SauerR.; German Rectal Cancer Study Group: Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94.Int J Radiat Oncol Bol Phys, 67: 1008–1019, 2007.
38.
ValentiniV., AristeiC., GlimeliusB., MinskyB.D., Beets-TanR., BorrasJ.M., HaustermansK., MaingonP., OvergaardJ., PahlmanL., QuirkeP., SchmollH.J., Sebag-MontefioreD., TaylorI., Van CutsemE., Van de VeldeC., CelliniN., LatiniP., on behalf of the Scientific Committee: Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2).Radiother Oncol, 92: 148–163, 2009.
De PaoliA., ChiaraS., LuppiG., FrisoM.L., BerettaG.D., Del PreteS., PasettoL., SantantonioM., SartiE., MantelloG., InnocenteR., FrustaciS., CorvòR., RossoR.: Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.Ann Oncol, 17: 246–251, 2006.
42.
De BruinA.F.J., NuyttensJ.J., FerenschildF.T., PlantingA.S., VerhoefC., de WiltJ.H.: Preoperative chemoradiation with capecitabine in locally advanced rectal cancer.Neth J Med, 66: 71–76, 2008.
43.
ValenikV., AnderluhF., OblakI., StrojanP., ZakotnikB.: Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.Croat Med J, 47: 693–700, 2006.
44.
KimJ.C., KimT.W., KimJ.H., YuC.S., KimH.C., ChangH.M., RyuM.H., ParkJ.H., AhnS.D., LeeS.W., ShinS.S., KimJ.S., ChoiE.K.: Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.Int J Radiat Oncol Biol Phys, 63: 346–353, 2005.
45.
DunstJ., DebusJ., RudatV., WulfJ., BudachW., HoelscherT., ReeseT., MoseS., RoedelC., ZuehlkeH., HinkeA.: Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.Strahlenther Onkol, 184: 450–456, 2008.
46.
HyamsD.M., MamounasE.P., PetrelliN., RocketteH., JonesJ., WieandH.S., DeutschM., WickerhamL., FisherB., WolmarkN.: A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Adjuvant Breast and Bowel Project protocol R-03.Dis Colon Rectum, 40: 131–139, 1997.
47.
VeerasarnV., BoonnuchW., ChinswangwatanakulV., LohsiriwatD., MahamadsolaehP.: Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.J Med Assoc Thai, 91: 1583–1588, 2008.
48.
PignonT., HoriotJ.C., BollaM., van PoppelH., BartelinkH., RoelofsenF., PeneF., GerardA., EinhornN., NguyenT.D., VanglabbekeM., ScallietP.: Age is not a limiting factor for radical radiotherapy in pelvic malignancies.Radiother Oncol, 42: 107–120, 1997.
49.
Colorectal Cancer Collaborative Group:Surgery for colorectal cancer in elderly patients: a systematic review.Lancet, 356: 968–974, 2000.
50.
ChiappaA., ZbarA.P., BertaniE., BiellaF., AudisioR.A., StaudacherC.: Surgical outcomes for colorectal cancer patients including the elderly.Hepatogastroenterology, 48: 440–444, 2001.
51.
AuH.J., MulderK.E., FieldsA.L.: Systematic review of management of colorectal cancer in elderly patients.Clin Colorectal Cancer, 3: 165–171, 2003.
52.
KohneC.H., GrotheyA., BokemeyerC., BontkeN., AaproM.: Chemotherapy in elderly patients with colorectal cancer.Ann Oncol, 12: 435–442, 2001.
53.
BujkoK., NowackiM.P., Nasierowska-GuttmejerA., MichalskiW., BebenekM., KryjM.: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.Br J Surg, 93: 1215–1223, 2006.
54.
GoldbergP.A., NichollsR.J., PorterN.H., LoveS., GrimseyJ.E.: Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure.Eur J Cancer, 30: 1602–1606, 1994.
55.
LiuG., FranssenE., FitchM.I., WarnerE.: Patient preferences for oral versus intravenous palliative chemotherapy.J Clin Oncol, 15: 110–115, 1997.
56.
KrishnanS., JanjanN.A., SkibberJ.M., Rodriguez-BigasM.A., WolffR.A., DasP., DelclosM.E., ChangG.J., HoffP.M., EngC., BrownT.D., CraneC.H., FeigB.W., MorrisJ., Vadhan-RajS., HamiltonS.R., LinE.H.: Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.Int J Radiat Oncol Biol Phys, 66: 762–771, 2006.
